ArticleNature communications2026
Blood-brain barrier-penetrant nanotherapy inhibits haem oxygenase-1-mediated ferroptosis for post-resuscitation neuroprotection.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cardiac arrest (CA) induces global ischaemia-reperfusion (I/R) injury that results in extensive neuronal damage and high rates of mortality and cognitive impairment, yet effective neuroprotective therapies remain lacking. A major barrier to intervention is the blood-brain barrier (BBB), which restricts drug access to injured brain tissue. Here, we present a BBB-penetrant nanotherapy that combines zwitterionic poly (tertiary amine oxide)-based micelles (OPDEA) with pleiotropic neuroprotectant artesunate (Art). The resulting formulation (OAMs) efficiently crosses the intact BBB via adsorptive-mediated transcytosis and accumulates in hippocampal neurons and microglia. Using in vitro hypoxia-reoxygenation and in vivo male mouse CA/cardiopulmonary resuscitation (CPR) models, we identify haem oxygenase-1 (HMOX1)-mediated ferroptosis as a key mechanism of post-resuscitation neuronal injury. OAMs suppress HMOX1 activity, restore iron homeostasis, and alleviate lipid peroxidation, thereby preserving mitochondrial function and neuronal viability. This work defines the HMOX1-ferroptosis axis as a tractable therapeutic target and positions OPDEA micelles as a BBB-penetrant nanoplatform for neuroprotection after CA and potentially other central nervous system diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.